Mammalian target of rapamycin (mTOR) antagonists

Breast Cancer Research

Volumn 6, Issue 5, 2004, Pages 219-224

  Carraway, Hetty ^a   Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CCI 779; Epidermal factor receptor; Mammalian target of rapamycin; Phosphatidylinositol 3 kinase pathway; PTEN

Indexed keywords

AP 23573; CORTICOSTEROID; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; EVEROLIMUS; MEMBRANE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL METABOLISM; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOWNSTREAM PROCESSING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DYSFUNCTION; LIPID DIET; MAMMAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; ANIMAL; BREAST TUMOR; CELL CYCLE; METABOLISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 4544315354     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr927     Document Type: Review

References (39)

1. Tee AR, Manning BD, Roux PP Cantley LC, Blenis J: Tuberous sclerosis complex gene products, Tuberin and Hararin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003, 13:1259-1268.
2. Manning BD, Cantley LC: Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003, 28:573-576.
3. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003, 2:296-313.
4. Aronica SM, Katzellenbogen BS: Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3′,5′-monophosphate, and insulin like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology 1991, 128:2045-2052.
5. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: Her-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells. Oncogene 1995, 10:2435-2446.
6. Smith CL: Crosstalk between peptide growth factor and estrogen receptor signaling pathways. Bio Reprod 1998, 58:627-632.
7. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol-3-kinase/Akt mediated activation of estrogen alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824.
8. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212.
9. Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Fruman D: The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo [abstract 2000]. Proc Am Assoc Cancer Res 1999, 40:301.
10. Guba M, von Breitenbuch F, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:10031-10033.
11. Eng CP, Seghgal SN, Vezina C: Activity of rapamycin (AY-22, 989) against transplanted tumors. J Antibio (Tokyo) 1984, 37: 1231-1237.
12. Dilling MB, Dias P, Shapiro DN: Rapamycin selectively inhibits growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin growth receptor. Cancer Res 1994, 54:903-907.
13. S6K phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996, 56:3895-3897.
14. Fry MJ: Phosphoinositide 3-kinase signaling in breast cancer: how big a role might it play? Breast Cancer Res 2001, 3:304-312.
15. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT: Ras dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995, 268:100-102.
16. Lee AV, Yee D: Insulin like growth factors and breast cancer. Biomed Pharmacother 1995, 49:415-421.
17. Scheid MP, Woodgett JR: Phosphatidylinositol-3 kinase signaling in mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2001, 6:83-99.
18. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
19. Smith GD, Gunnell D, Holly J: Cancer and insulin like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ 2000, 321:847-848.
20. Pollack M: Insulin like growth factor physiology and cancer risk. Eur J Cancer 2000, 36:1224-1228.
21. Yu H, Rohan T: Role of the insulin like growth factor family in cancer development and progression. J Natl Cancer Inst 2000, 92:1472-1489.
22. Lee AV, Hilsenbeck SG, Yee D: IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 1998, 47:295-302.
23. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
24. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of estrogen receptor with the regulatory subunit of phosphatidyl-inositol-3-OH-kinase. Nature 2000, 407:538-541.
25. deGraffenried L, Friedrichs W, Fulcher L, Silva J, Roth R, Hidalgo M: The mTOR inhibitor, CCI-779, restores tamoxifen response in breast cancer cells with high Akt activity. Roc 14th NCI-EORTC-AACR symposium on molecular targets and cancer therapeutics [abstract #528]. Eur J Cancer 2002, S158.
26. Cui X, Zhang F, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV: IGF-I inhibits progesterone expression in breast cancer via the PI3K/AKT/mTOR pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003, 17:575-588.
27. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in breast cancer. Oncogene 1993, 8:2127-2133.
28. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence IA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malilgnant lesions. Nat Med 1995, 1:1257-1259.
29. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62: 4132-4141.
30. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997, 57:3657-3659.
31. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, et al.: The role of genetic abnormalities of PTEN and the phosphatidylinosiyl 3 kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001, Suppl 16:125-141.
32. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, et al.: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999, 155: 1253-1260.
33. Stål O, Pérez-Tenorio G, Akerberg L, Olsson B, Nordenskjöld B, Skoog L, Rutqvist LE: AKT kinases in breast cancer and results of adjuvant therapy. Breast Cancer Res 2002, 5:R37-R44.
34. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL: Enhanced sensitivity of PTEN- deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001, 98:10314-10319.
35. Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62:6141-6145.
36. Rudloff J, Boulay A, Zumstein-Mecker S, Evans DB, O'Reilly T, Lane H: The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas [abstract]. Proc Am Assoc Cancer Res 2004, 45:A5619.
37. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol; 2004, 22:2336-2347.
38. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, et al.: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
39. Chan S, Scheulen ME, Johnston S, Mross K, Piccart M, Hess D, Bouxin N, Azli N: Final results of a phase 2 study of single agent CCI-779 in locally advanced or metastatic breast cancer failing prior anthracyclin and/or taxane regimens [abstract 346]. Breast Cancer Res Treat 2003, 82:s82.